Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma

BackgroundTumor mutational burden (TMB) plays an important role in the evaluation of immunotherapy efficacy in lung adenocarcinoma (LUAD).ObjectiveTo improve the clinical management of LUAD by investigating the prognostic value of TMB and the relationship between TMB and immune infiltration.MethodsT...

Full description

Bibliographic Details
Main Authors:	Lin Li, Junyu Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Oncology
Subjects:	lung adenocarcinoma tumor mutation burden immune checkpoint blockade the cancer genome atlas cell proliferation
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1128785/full

Similar Items

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01)

Analysis of Nucleoporin 107 Overexpression and Its Association with Prognosis and Immune Infiltration in Lung Adenocarcinoma by Bioinformatics Methods
by: Li ZH, et al.
Published: (2023-11-01)

Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report
by: Eva Katharina Egger, et al.
Published: (2021-07-01)

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
by: Congkuan Song, et al.
Published: (2021-01-01)

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma
by: Yulan Zhao, et al.
Published: (2022-08-01)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
by: Yuchun Niu, et al.
Published: (2020-08-01)

Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures
by: Chen Huo, et al.
Published: (2021-07-01)

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
by: Mingming Jia, et al.
Published: (2020-02-01)

Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability
by: Dongdong Yang, et al.
Published: (2021-02-01)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
by: Luochengling Xiang, et al.
Published: (2020-09-01)

Development and validation of an interpretable radiomic signature for preoperative estimation of tumor mutational burden in lung adenocarcinoma
by: Yuwei Zhang, et al.
Published: (2024-04-01)

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
by: Jia Li, et al.
Published: (2021-09-01)

Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma
by: Jiang Zhengsong, et al.
Published: (2023-03-01)

RETRACTED ARTICLE: Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma
by: Yu Zhang, et al.
Published: (2023-08-01)

CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma
by: Li Z, et al.
Published: (2022-04-01)

Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma
by: Ying Li, et al.
Published: (2020-01-01)

Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma
by: Rui Li, et al.
Published: (2020-10-01)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
by: Timothy V. Pham, et al.
Published: (2020-08-01)

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
by: Shangshang Ma, et al.
Published: (2024-12-01)

Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas
by: Mark Menor, et al.
Published: (2019-01-01)

Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer
by: Huanlan SA, et al.
Published: (2019-06-01)

Upregulation of Long Non-Coding RNA GCC2-AS1 Facilitates Malignant Phenotypes and Correlated With Unfavorable Prognosis for Lung Adenocarcinoma
by: Fengqiang Yu, et al.
Published: (2021-01-01)

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis
by: Junya Yan, et al.
Published: (2020-11-01)

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
by: Dejun Zeng, et al.
Published: (2021-10-01)

A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients
by: Yuquan Bai, et al.
Published: (2022-05-01)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
by: He Li, et al.
Published: (2023-04-01)

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses
by: Wenlong Zhang, et al.
Published: (2023-06-01)

Identification and Validation of Two Lung Adenocarcinoma-Development Characteristic Gene Sets for Diagnosing Lung Adenocarcinoma and Predicting Prognosis
by: Cheng Liu, et al.
Published: (2020-12-01)

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
by: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Published: (2021-11-01)

Identification of potential biomarkers for lung adenocarcinoma
by: Deepak Sayeeram, et al.
Published: (2020-11-01)

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma
by: Qian Song, et al.
Published: (2019-03-01)

Identification of LBX2 as a novel causal gene of lung adenocarcinoma
by: Jingwen Hu, et al.
Published: (2020-08-01)

Genomic and immunologic correlates of LAG-3 expression in cancer
by: Anshuman Panda, et al.
Published: (2020-01-01)

Differentially expressed and survival‐related proteins of lung adenocarcinoma with bone metastasis
by: Mengdi Yang, et al.
Published: (2018-04-01)

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
by: Jinchul Kim, et al.
Published: (2020-03-01)

The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma
by: Xiaozhou Yu, et al.
Published: (2021-10-01)

The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer
by: Xiangzheng Liu, et al.
Published: (2021-08-01)

Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism‐related genes
by: Zhihao Wang, et al.
Published: (2021-04-01)

SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma
by: Xiuao Zhang, et al.
Published: (2022-04-01)

STK11 mutation affects tumor proliferation by impacting CD4+ T cell activity in lung adenocarcinoma
by: Jiemeng Ge, et al.
Published: (2024-10-01)